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ABSTRACT 
Hypertension, which affects 1 billion adults 
worldwide, is a risk factor for cardiovascular 
and renal disease. The epidemiological studies 
carried out on hypertension States those 
hypertension patients are more in urban area as 
compared to rural population. Indian studies 
are in contradiction with the studies conducted 
in world. Hypertension is define as increase in 
blood pressure above the normal range which is 
120/80 mmHg. Blood pressure mainly consist of 
2 types systolic and diastolic  
1. Systolic pressure- 90-120  
2. Diastolic pressure- 60-80 
 
Physiologically the blood pressure controlled by 
two main types of system one is adrenergic 
system and another is rennin–angiotensin-
aldosterone system. This article mainly discusses 
the types of hypertension, classification, 
pathogenesis, the main focus on treatment. 
 
Keywords-- Death rate, diabetes, Hypertension, 
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INTRODUCTION 
 
Effective treatment of hypertension is an 
important part of any program to reduce the 
incidence of cardiovascular disease. In daily life, 
doctors prescribe antihypertensive drugs to people 
with high blood pressure. 
 
Types of Hypertension 
 
There are mainly two types of hypertension: 
1-Primary: High blood pressure is not correlated 
to a different medical situation 
2-Secondary: one more medical situation that 
causes high blood pressure, typically taking place 
in the kidneys, arteries, heart, or endocrine system. 
Examples include: 
 Sleep troubles like sleep apnea 
 uncreative renal arteries in the kidneys 
 abnormal levels of hormones calculating 
blood pressure 
 
 
 
Figure 1: Difference Between Primary and Secondry Hypertension. 
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Figure 2: Hypertension across Women Life Cycle [7]. 
 
RELATION BETWEEN DIABETES AND 
HYPERTENSION 
  
 Diabetes and high blood pressure are expected 
to arise mutually as they divide definite 
physiological distinctiveness. High blood 
pressure is a high-risk condition that is even 
more difficult in the case of diabetes.  
 Hypertensive citizens are 2.5 times more 
possible to expand diabetes mellitus in five 
years. This might be due to the incidence of 
an essential metabolic disease and made 
inferior by the type of antihypertensive drug 
use.  
 In addition to the insulin battle is usually the 
cause of high blood pressure. Improved 
hepatic glucose release and insulin warming 
are caused by the activation of angiotensin II 
and aldosterone and renin-angiotensin 
aldosterone method (RAAS). 
 The symbiosis of DM and hypertension is 
detrimental to the cardiovascular system, 
resulting in increased risk of caress or 
cardiovascular death. Special analysis has 
suggested that some antihypertensive drugs 
confirm the progression of type-2-diabetes 
mellitus. 
 Various studies have shown that glucose 
metabolism is adversely affected by beta 
blockers and diuretics; therefore, not only 
infectivity but also antihypertensive therapy 
can lead to an increase in new-onset diabetes.  
 In addition, there is a long-standing record of 
potentially disturbing gluco-metabolic 
parameters due to high blood pressure 
medications, such as - 
Blood glucose 
Insulin sensitivity 
HbA1c. 
 Specifically, diuretics such as beta-blockers 
(so-called cardio-selective ones) and diuretics 
such as thiazide / thiazide have also been 
known to increase blood glucose for many 
years, as well as the risk of hyperosmolarity. 
 Hyperglycemic coma in the latter high dose. 
Therefore, whether or not antihypertensive 
drugs that raise blood glucose should be 
avoided seems to be an important issue, i.e., 
drugs that increase glycemic in diabetic 
patients or new traumatic diabetic stimulants 
in patients with hypertension [8]. 
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Figure 3: Classification of Drugs. 
 
 
 
Figure 4: Mechanism action of Hypertension. 
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Figure 5: Pathogenesis of Hypertension. 
 
ANTIHYPERTENSIVE DRUG EFFECT  
 
1. Anti-oxidant activity 
2. Opioid agonist activity 
3. Anti-inflammatory activity  
4. Rennin inhalation 
5. Calcium channel blocking 
6. Prostaglandin release 
7. Increased nitric oxide 
production[https://www.mdpi.com/1422-
0067/16/1/256/htm] 
 
HYPERTENSION-MEDIATED ORGAN 
DAMAGE 
Definition 
 
 Mediated organ harm in hypertension the 
board Hypertension-interceded organ harm 
(HMOD) is characterized as the basic or 
utilitarian modification of the blood vessel 
vasculature as well as the organs it supplies 
that is brought about by raised BP.  
 Finished organs incorporate the mind, the 
heart, the kidneys, focal and fringe supply 
routes, and the eyes. 
 While estimation of generally cardiovascular 
risk is generally significant for the 
administration of hypertension, extra 
determination of HMOD is unlikely to change 
the administration of those patients previously 
recognized as high hazard (for example those 
with built up CVD, stroke, diabetes, CKD, or 
familial hypercholesterolemia).However, it 
can give significant helpful direction on 
1. Because of presence of HMOD, management 
for hypertensive patients with low or modest 
overall risk throughout by re-arrangement. 
2. Privileged choice of drug treatment depends 
on the definite impact on HMOD. 
 
DEFINITE ASPECTS OF HMOD AND 
ASSESSMENT BRAIN 
  
For elevated BP common manifestations 
are TIA or strokes .Untimely subclinical changes 
can be detected most perceptively by MRI and 
consist of white matter lesions, silent micro 
infarcts, micro bleeds, and brain atrophy. Because 
of costs and inadequate accessibility, brain MRI is 
not optional for usually observe but should be 
considered in individuals with neurologic 
instability, cognitive refuse and remembrance loss.  
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Heart 
 
1. A 12-lead Electrocardiogram is not 
compulsory for usual practice of patients with 
hypertension and plain criteria (Sokolow–
Lyon index: SV1þRV5 35mm, Cornell index: 
SV3þRaVL >28 mm for men or >20mm for 
women and Cornell voltage interval product: 
>2440 mms) are accessible to detect 
occurrence of LVH. Sensitivity of ECG-LVH 
is inadequate and a two-dimensional 
transthoracic echocardiogram (TTE) is the 
technique of selection to precisely assess LVH 
[left ventricular mass index (LVMI): men 
>115 g/m2  
2. Simplified classification of hypertension 
threat, according to further risk factors, 
HMOD and prior disease. Other risk features, 
HMOD, or disease High-normal. No other 
threat factors – 
3. Low Low Moderate 
4. High Low Moderate High Low  
5. Moderate High High diabetes mellitus 
6. CVD High Example based on a 60-year-old 
male patient. Categories of threat will differ 
according to age and sex.. All rights are held 
in reserve. LV geometry, left atrial volume, 
LV systolic and diastolic function are 
significant parameters. 
 
Kideny 
 
 Kidney disappointment can be a reason and 
significance of hypertension and is best evaluated 
routinely by basic renal capacity boundaries (serum 
creatinine and eGFR) commonly with assessment 
for albuminuria [dipstick or urinary egg whites 
creatinine proportion (UACR) in untimely morning 
spot pee. 
 
Arteries 
Three vascular beds are frequently assessed to 
perceive arterial HMOD: 
 
1. The carotid arteries throughout carotid 
ultrasound to notice atherosclerotic plaque 
trouble/stenosis and intima–media width 
(IMT). 
2. The aorta by carotid—femoral pulse wave 
velocity (PWV) assessment to detect large 
artery stiffening; and the inferior limit arteries 
by assessment of the ankle–brachial index 
(ABI). 
3. Even though there is confirmation to 
designate that all three grant added value 
further than traditional risk factors, their usual 
use is presently not suggested except 
clinically indicated, that is, in patients with 
neurologic symptoms, remote of systolic 
hypertension, or alleged peripheral artery 
disease, correspondingly. 
 
Eyes 
 
1. Fundoscopy is a simple clinical bedside test to 
screen for hypertensive retinopathy although 
inter observer and intra observer 
reproducibility is inadequate. 
2. Fundoscopy is predominantly important in 
hypertensive urgencies and emergencies to 
perceive retinal haemorrhage, micro 
aneurysms, and papilledema in patients with 
accelerated or malignant hypertension. 
3. In grade 2 hypertension patients , Fundoscopy 
should be performed , preferably by 
knowledgeable examine 
 
The following assessments to detect HMOD 
should be performed normally in all patients 
with hypertension 
 
1. Serum creatinine and eGFR dipstick urine test 
12-lead ECG are the techniques mentioned 
above can add value to optimize management 
of hypertension in exaggerated individuals 
and should be considered wherever clinically 
indicated and existing. 
2. Serial assessment of HMOD (LVH and 
albuminuria) to observe failure with 
antihypertensive treatment may be supportive 
to establish the efficiency of treatment in 
individual patients but this has not been 
satisfactorily validated for most measures of 
HMOD. 
 
EXACERBATORS AND INDUCERS OF 
HYPERTENSION 
 
1. some medications and substances may raise 
BP or provoke the BP-lowering effects of 
antihypertensive treatment in individuals  
2. It is important to reminder that the individual 
cause of these substances on BP can be highly 
uneven with superior increases renowned in 
the elderly, those with elevated baseline BP, 
using antihypertensive treatment or with 
kidney disease.  
3. Monitor all patients (with hypertension and 
those at threat for hypertension) for 
substances that may raise the BP or obstruct 
with the BP-lowering consequence of 
antihypertensive medications.  
4. Where suitable, consider reducing or 
eliminating substances that elevate BP. If 
these substances are obligatory or chosen, 
then treat BP to aim despite. On probable 
antihypertensive therapies that target 
mechanisms essential the raised BP induced 
by these substances. 
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SIGN AND SYMPTOM 
 
1. 1-Severe headache 
2. 2-Fatigue or confusion 
3. 3-Vision problems 
4. 4-Chest pain 
5. 5-Difficulty breathing 
6. 6-Irregular heartbeat 
7. 7-Blood in the urine 
8. 8-Pounding in your chest, neck, or ears 
 
TREATMENT 
Controlled Diet 
1. Nutritional changes are supported to reduce 
high blood pressure and for early 
management. 
2.  In hypertensive patients, in addition to a 
balanced diet, sodium intake of 65 to 100 mm 
/ day is not sufficient.  
 
Other suggestions are 
 
1. Low Diet in inundated fat and cholesterol 
2. One that emphasize fruits 
3. Vegetables and low-fat dairy products 
4. Dietary and soluble fiber 
5. Whole grains and protein from plant sources. 
Alcohol drinking should be mod
 
 
Figure 6: Healthy Lifestyle. 
 
Reduced Salt Intake 
 
In animal studies, epidemiological studies, 
experimental tests, and meta-analyzes suggest that 
an increase in dietary salt (sodium chloride) also 
leads to an increase in BP. suggestion about the 
personal effects of salt on BP comes from 
cautiously illicit, dose response trials. Each of these 
trials experienced sodium levels and accepted 
essential relationships
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Figure 7: Tips to Reduce Salt Intake. 
 
Too much of salt can lead to following health 
complications 
 
1. High Blood Pressure  
2. Damages Kidneys 
3. Weakens bones  
4. Obesity  
5. Clogged Arteries 
6. Stroke 
7. Heart Attack 
8. Damages Brain 
 
Physical Activity 
 
The Longitudinal intervention study is 
more appropriate for assessing the properties of 
physical movements. A meta-analysis of 
randomized trials reported that a decrease in 
aerobic applied signal systolic (-3.84 mm Hg) as 
well as diastolic BP (-2.58 mm Hg) was inevitably 
added. This reduction was experimental in 
hypertensive as well as non-muscular individuals 
and in specific weight as well as obesity 
participants.
 
Figure 8: Benefits of Physical Activity. 
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Figure 9: Death Rate. 
 
CONCLUSION 
 
Hypertension is a very important disease 
in the elderly and is associated with an increased 
risk of cardiovascular malformations and death. 
The fact that dropping blood pressure values 
reduces the risk of heart attack as well as 
neurological, metabolic and muscular dystrophy in 
the elderly. 
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